DNA FOR THE SYNTHETIC BIOLOGY REVOLUTION
THE FUTURE OF DNA
We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale.
To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.
Fueling the Synthetic Biology Revolution
FOOD & AG
Creating sustainable, abundant food sources is one of the most important goals of synthetic biology, and desperately needed as our resources shrink and our needs grow.
CHEMICALS
Biology has been creating compounds through enzymatic chemistry before humans were around. Let's tap into the world's oldest green chemical manufacturing process and evolve it to create new chemicals.
MATERIALS
From petrochemical based polymers to clothing, synthetic biology has the power to re-create our everday materials in a more green and sustainable way.
OUR PEOPLE
Matt Hill, PhD
Founder and CEO
Matt Hill is a driven by a mission to create a lasting positive impact on the world. He holds a PhD in Genetics from Stanford, and was previously Vice President of Research and Development at Natera where he co-invented their core technology and led the commercialization of five precision molecular diagnostic products. This included Natera’s best-in-class noninvasive prenatal test, which has been used by millions ensure healthy pregnancies, and which enabled Natera’s 2015 IPO. He founded Elegen to solve DNA writing and unlock the synthetic biology revolution.
Marc Unger, PhD
CSO
Marc A. Unger received his PhD in Physical Chemistry at Caltech. During a postdoc in Applied Physics in Professor Steve Quake’s lab, he invented Multilayer Soft Lithography, the foundational technology of Fluidigm Corporation. The first paper describing the technology was published in Science and has now been cited more than 4000 times. He joined Fluidigm and drove the development of the core technology, manufacturing, and product lines; he served as VP R&D and Chief Scientific Officer. He also restructured and rebuilt the Marketing organization as EVP R&D and Marketing. During his tenure the company went public and achieved product revenues greater than $100M per year.
Dan La Caze
CBO
Dan has over 16 years experience in corporate and business development roles at life science and molecular diagnostics companies, including Sequenom, Genoptix (Novartis), Natera and most recently Berkeley Lights. He has led over 100 strategic transactions, on both the buy- and sell-side and has developed successful corporate strategies for small- and medium-sized biotechnology companies with disruptive technologies. He has a BS and MS in Biology from UCSD and a MBA from London Business School.
Investors
CAREERS
Elegen is developing a suite of innovative technologies to unlock the SynBio revolution, and we need the best and brightest to succeed. For all our positions, there will be substantial opportunities for career growth and development as the company grows, including leadership opportunities for suited individuals.
LOCATION
MBC BIOLABS
SAN CARLOS, CA